Operational Improvements Will Unlock Biotech Potential And China Market Expansion

Published
23 Feb 25
Updated
21 Aug 25
AnalystConsensusTarget's Fair Value
AU$288.61
21.7% undervalued intrinsic discount
21 Aug
AU$226.00
Loading
1Y
-26.6%
7D
-16.3%

Author's Valuation

AU$288.6

21.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on20 Aug 25
Fair value Decreased 7.20%

CSL's consensus price target has been revised downward, reflecting a material drop in expected revenue growth alongside a sharply higher future P/E ratio, with fair value now set at A$291.99. What's in the News CSL expects group revenue growth of approximately 4-5% and NPATA growth of 7-10% for FY26, excluding non-recurring restructuring costs.

Shared on01 May 25
Fair value Decreased 0.53%

Shared on23 Apr 25
Fair value Increased 0.96%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 5.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.05%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 1.04%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 1.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.